Tumor-targeted bioluminescent bacteria have been shown for the first time to provide accurate 3D images of tumors in mice, further advancing the potential for targeted cancer drug delivery, according to a study published in the Jan. 25 issue of the online journal PLoS ONE.
The specially engineered probiotic bacteria, like those found in many yoghurts, were intravenously injected into mice with tumors, after which the researchers took full body bioluminescent images. The 3D images revealed information about the number and location of the bacteria, to the level of precisely revealing where within the tumour the bacteria were living, providing much more information on the interaction of bacteria and tumors than was previously available using similar two-dimensional imaging methods.
According to the authors, led by Mark Tangney of University College Cork in Ireland, "before now, researchers used luminescence to provide an approximation of where a test organism was within the body, and would then follow up with multiple further experiments using different techniques to try to find a precise location". This new research suggests that such bacteria can be engineered to contain diagnostic or therapeutic agents that would be produced specifically within the tumor for targeted treatment.
Citation: Cronin M, Akin AR, Collins SA, Meganck J, Kim J-B, et al. (2012) High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting. PLoS ONE 7(1): e30940. doi:10.1371/journal.pone.0030940
Financial Disclosure: The authors wish to acknowledge support relevant to this manuscript from the European Commission Seventh Framework Programme (PIOF-GA-2009-255466) and the Irish Health Research Board (HRA_POR/2010/138). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interest Statement: AA, JM, J-BK, NZ and KF are employees of Caliper Life Sciences. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Disclaimer: This press release refers to upcoming articles in PLoS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
About PLoS ONE
PLoS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLoS ONE is published by the Public Library of Science (PLoS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.
All works published in PLoS ONE are Open Access. Everything is immediately available--to read, download, redistribute, include in databases and otherwise use--without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLoS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.